PT - JOURNAL ARTICLE AU - Toscano-Guerra, Emily AU - Maggio, Valentina AU - García, Javier AU - Semidey, Maria Eugenia AU - Celma, Ana AU - Morote, Juan AU - Torres, Inés de AU - Giralt, Marina AU - Ferrer, Roser AU - Paciucci, Rosanna TI - Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures and serum samples from a European Caucasian population AID - 10.1101/2024.01.07.24300896 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.07.24300896 4099 - http://medrxiv.org/content/early/2024/01/08/2024.01.07.24300896.short 4100 - http://medrxiv.org/content/early/2024/01/08/2024.01.07.24300896.full AB - Prostate cancer (PCa) is the most common cancer in men and the third leading cause of cancer death in Europe. The TP53 gene, the most frequently mutated gene in human cancer, is a tumor suppressor gene with crucial functions in preventing tumor development. The single nucleotide polymorphism rs1042522, characterized by the substitution of a proline (PRO) for an arginine (ARG) at the position 72 of the p53 protein (P72R SNP), was studied in 12 primary tumor cultures from prostate biopsies of untreated hormone-naïve patients (hnPCs) with aggressive-metastatic cancer (Gleason ≥8), 11 radical prostatectomies, and a cohort of 94 serums from patient with aggressive prostate cancer using DNA sequencing and melting curve analysis. The results identified a high frequency of the P72R SNP in prostate cancer samples compared to the general European (non-cancer) population, suggesting a very significant association (p<0.0001) between this SNP and the risk of prostate cancer with an odds ratio of 7.937 (IC 95% 5.37-11.00). The G allele (R72) was more frequent in patients with high Gleason scores (≥8) suggesting its association to more undifferentiated-malignant PCa lesions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by grants from the Ministerio de Ciencia e Innovacion (RTI2018-096055-B-I00)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Research Ethics Committee of Vall d`Hebron Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors